Moderna president sells 53,336 shares after option exercise

Moderna President Stephen Hoge reported an option exercise and share sale in company stock on July 15, 2026.

Rhea-AI Filing Summary

Moderna President Stephen Hoge reported an option exercise and share sale in company stock on July 15, 2026. He exercised stock options to acquire a total of 53,336 shares of common stock at an exercise price of $19.15 per share, then sold 53,336 shares in open-market transactions at $67.60 per share pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2025. Following these transactions, he reports 1,483,848 shares held directly, plus indirect interests in 151,933 shares held by a trust for the benefit of his spouse and children and 4,116 shares held by Valhalla, LLC, with beneficial ownership of the trust shares disclaimed except for any pecuniary interest.

Insider Trade Summary 10b5-1

Exercise and Sale: 53,336 shares ($2.58M approx. pre-tax spread)

Exercise and Sale 7 txns

Insider Hoge Stephen

Role President

Sold 53,336 shs ($3.61M)

Approx. gross sale proceeds $3.61M

Approx. exercise cost $1.02M

Approx. pre-tax spread $2.58M

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy) F1, F3	37,226	$0.00	$0.00
Exercise	Stock Option (Right to Buy) F1, F3	16,110	$0.00	$0.00
Exercise	Common Stock F1	37,226	$19.15	$713K
Exercise	Common Stock F1	16,110	$19.15	$309K
Sale	Common Stock F1	53,336	$67.60	$3.61M
holding	Common Stock	--	--	--
holding	Common Stock F2	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 0 contracts (Direct); Common Stock — 1,483,848 shares (Direct); Common Stock — 4,116 shares (Indirect, By Valhalla, LLC); Common Stock — 151,933 shares (Indirect, By Trust)

Footnotes (3)

1. F1. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2025.
2. F2. These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
3. F3. This option is fully vested and exercisable.

Key Figures

Shares sold: 53,336 shares Sale price: $67.60 per share Options exercised (tranche 1): 16,110 shares at $19.15 +4 more

7 metrics

Shares sold 53,336 shares Common stock sold in open-market transaction on July 15, 2026 at $67.60 per share

Sale price $67.60 per share Price for 53,336 shares of Moderna common stock sold on July 15, 2026

Options exercised (tranche 1) 16,110 shares at $19.15 First stock option tranche exercised into common stock on July 15, 2026

Options exercised (tranche 2) 37,226 shares at $19.15 Second stock option tranche exercised into common stock on July 15, 2026

Direct holdings after transactions 1,483,848 shares Common stock directly held by Stephen Hoge following July 15, 2026 transactions

Family trust holdings 151,933 shares Shares held by a trust for the benefit of Hoge’s spouse and children

Valhalla, LLC holdings 4,116 shares Shares of Moderna common stock held indirectly through Valhalla, LLC

Key Terms

Rule 10b5-1 trading plan, Section 16 beneficial ownership, Stock Option (Right to Buy), pecuniary interest

4 terms

Rule 10b5-1 trading plan regulatory

"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2025"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Section 16 beneficial ownership regulatory

"The reporting person disclaims Section 16 beneficial ownership of these securities"

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy) with an exercise price of 19.1500"

pecuniary interest financial

"except to the extent of his pecuniary interest therein, if any"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Moderna (MRNA) President Stephen Hoge report on July 15, 2026?

Stephen Hoge reported exercising options to acquire 53,336 Moderna shares at $19.15 per share and selling 53,336 shares at $67.60 per share. The sales were executed under a pre-established Rule 10b5-1 trading plan adopted on November 13, 2025.

How many Moderna (MRNA) shares did Stephen Hoge sell and at what price?

Stephen Hoge sold 53,336 shares of Moderna common stock at an average price of $67.60 per share. These open-market sales occurred on July 15, 2026 and were made pursuant to a Rule 10b5-1 trading plan he adopted in November 2025.

What stock options did Stephen Hoge exercise in Moderna (MRNA) on July 15, 2026?

Hoge exercised fully vested stock options covering 16,110 shares and 37,226 shares, for a total of 53,336 shares of Moderna common stock. Both option tranches had an exercise price of $19.15 per share and an expiration date of August 10, 2026.

How many Moderna (MRNA) shares does Stephen Hoge hold after these transactions?

After the reported transactions, Stephen Hoge directly holds 1,483,848 shares of Moderna common stock. He also reports indirect interests in 151,933 shares through a family trust and 4,116 shares through Valhalla, LLC, with a disclaimer of beneficial ownership for the trust shares except for pecuniary interest.

What indirect Moderna (MRNA) holdings related to Stephen Hoge are disclosed?

The filing lists 151,933 shares held by a trust for the benefit of Hoge’s spouse and children and 4,116 shares held by Valhalla, LLC. Hoge disclaims Section 16 beneficial ownership of the trust’s shares except to the extent of any pecuniary interest.

Were Stephen Hoge’s Moderna (MRNA) share sales made under a Rule 10b5-1 plan?

Yes. A footnote states the reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2025. Such pre-arranged plans allow insiders to sell shares under predetermined terms, helping manage trading while addressing potential conflicts.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/16/2026 - 04:45 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hoge Stephen

(Last) (First) (Middle)

C/O MODERNA, INC.

325 BINNEY STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Moderna, Inc. [ MRNA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/15/2026		M(1)		37,226	A	$19.15	1,521,074	D
Common Stock	07/15/2026		M(1)		16,110	A	$19.15	1,537,184	D
Common Stock	07/15/2026		S(1)		53,336	D	$67.6	1,483,848	D
Common Stock								4,116	I	By Valhalla, LLC
Common Stock								151,933	I	By Trust(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$19.15	07/15/2026		M(1)			37,226	(3)	08/10/2026	Common Stock	37,226	$0	0	D
Stock Option (Right to Buy)	$19.15	07/15/2026		M(1)			16,110	(3)	08/10/2026	Common Stock	16,110	$0	0	D

Explanation of Responses:

1. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2025.

2. These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

3. This option is fully vested and exercisable.

	/s/ James Dillon, as Attorney-in-Fact	07/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)